Press Releases Keyword Search Year None2022202120202019201820172016201520142013 April 11, 2022 Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10 April 8, 2022 Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting February 28, 2022 Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference February 24, 2022 Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates February 16, 2022 Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update January 10, 2022 Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference January 4, 2022 Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3
April 11, 2022 Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10
April 8, 2022 Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting
February 28, 2022 Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference
February 24, 2022 Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates
February 16, 2022 Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update
January 10, 2022 Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference
